Losartan for the treatment of hypertension and left ventricular hypertrophy: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study Review uri icon

Overview

MeSH Major

  • Angiotensin II Type 1 Receptor Blockers
  • Hypertension
  • Hypertrophy, Left Ventricular
  • Losartan

abstract

  • Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class. It has been approved for the treatment of hypertension, and may be used alone or in combination with other antihypertensive agents. Based on the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. Based on the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, losartan is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria, in patients with Type 2 diabetes. The focus of this review is the LIFE study.

publication date

  • November 2004

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1517/14656566.5.11.2311

PubMed ID

  • 15500378

Additional Document Info

start page

  • 2311

end page

  • 20

volume

  • 5

number

  • 11